Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

37results about How to "High antigen purity" patented technology

Dual-subunit vaccine against echinococcus granulosus and echinococcus multilocularis and method for preparing the same

This invention discloses a bivalent subunit vaccine against Echinococcus granulosus and Echinococcus cantonensis, and its preparation method. The bivalent subunit vaccine comprises the immunogen dEG95 / dEC95 antigen protein and a pharmaceutically acceptable carrier. The amino acid sequence of the dEG95 protein is shown in SEQ ID No. 1, and the amino acid sequence of the dEC95 protein is shown in SEQ ID No. 2. Currently, there are no vaccines that simultaneously protect against Echinococcus granulosus and Echinococcus cantonensis infection. This invention uses the dEG95-dEC95 heterodimeric protein as the antigen, and the prepared bivalent subunit vaccine against both Echinococcus granulosus and Echinococcus cantonensis has low production cost and a simple production process. It can simultaneously prevent infection by both Echinococcus granulosus and Echinococcus cantonensis, and has many advantages such as safety, high efficiency, low cost, and high antigen purity.
Owner:SHANGHAI SHEN LIAN BIOMEDICAL CORP

Binding proteins that specifically bind to mycoplasma pneumoniae p1 protein, methods of making and use

The application provides a binding protein specifically binding to Mycoplasma pneumoniae P1 protein, a preparation method and application, and relates to the technical field of biotechnology.The binding protein contains a heavy chain variable region and a light chain variable region, the complementarity determining region of the heavy chain variable region includes an amino acid sequence identical to VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO.1; the complementarity determining region of the light chain variable region includes an amino acid sequence identical to VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQ ID NO.2 or 3.The binding protein has good specific binding capacity to the Mycoplasma pneumoniae P1 protein, can also bind to Mycoplasma pneumoniae whole bacteria, and can be used for detection of Mycoplasma pneumoniae or Mycoplasma pneumoniae P1 protein, and detection and diagnosis of Mycoplasma pneumoniae or Mycoplasma pneumoniae infection.
Owner:ZHUHAI LIHE MEDICAL DIAGNOSTIC PROD CO LTD +1